Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

The drug, previously called KarXT, is an oral medication for the treatment of schizophrenia in adults. Cobenfy introduces a fundamentally new approach to treating schizophrenia by selectively ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Given these trial results, there remains uncertainty about emraclidine’s future prospects and AbbVie’s ability to present a competitive alternative in the schizophrenia treatment market, particularly ...

Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...

Karuna and it’s recently approved Cobenfy, or KarXT. This news “may also prove to be a substantial positive” for Neurocrine (NBIX) “if – and it’s admittedly a huge IF – the company can successfully ...

Leerink Partners raised its target for Bristol-Myers Squibb from $55 to $73, citing optimism for the company's products Cobenfy (KarXT) and milvexian, a novel blood thinner. Similarly, BMO Capital ...